Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
Theranostics|January 4, 2021
Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy responseDanny Feijtel, Gabriela N Doeswijk, Nicole S Verkaik, et al.Journal of Neurosurgery|October 29, 2022
Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgeryBianca M Dijkstra, Julie Nonnekens, Wouter Nagengast, et al.Theranostics|August 30, 2016
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor OlaparibJulie Nonnekens, Melissa van Kranenburg, Cecile E M T Beerens, et al.Cancer Medicine|September 9, 2025
Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear MedicineMara M K Veenstra, Sophie Veldhuijzen van Zanten, Erik Vegt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumorsMorticia N Becx, Johannes Hofland, Eric P Krenning, et al.The Prostate|December 7, 2018
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy responseWenhao Zhang, Wytske M van Weerden, Corrina M A de Ridder, et al.Cancers|July 12, 2025
Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal CellsZofia M Komar, Marjolijn M Ladan, Nicole S Verkaik, et al.EJNMMI Physics|February 11, 2020
Cellular dosimetry of [<sup>177</sup>Lu]Lu-DOTA-[Tyr<sup>3</sup>]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicityGiulia Tamborino, Marijke De Saint-Hubert, Lara Struelens, et al.Cell Reports|January 21, 2015
A Long Noncoding RNA on the Ribosome Is Required for Lifespan ExtensionPaul B Essers, Julie Nonnekens, Yvonne J Goos, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2022
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&TEline A M Ruigrok, Giulia Tamborino, Erik de Blois, et al.Pageof 6